Results 161 to 170 of about 3,726,940 (286)

Profiling neoadjuvant therapy response in rectal cancer using meta‐analysis of publicly available transcriptomic RNA‐seq datasets

Molecular Oncology, EarlyView.
This study integrates publicly available transcriptomic datasets to identify molecular signatures associated with response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer. By analyzing a combination of multiple cohorts with bioinformatics approaches, we reveal biological pathways and immune‐related features that may improve ...
Aleksandra Stanojevic, Rafael Stroggilos, Mladen Marinkovic, Ana Djuric, Suzana Stojanovic‐Rundic, Radmila Jankovic, Sergi Castellvi‐Bel, Remond J.A. Fijneman, Antonia Vlahou, Jerome Zoidakis, Milena Cavic   +10 more
wiley   +1 more source

Landslide Hazard Identification and Prediction in Complex Mountainous Areas Using Ascending and Descending Orbits InSAR Technology. [PDF]

Sensors (Basel)
Zhao W, Cong P, Ma X, Yi M, Liu C, Gao J, Zhang Y.   +6 more
europepmc   +1 more source

Comprehensive interpretation of in vitro micronucleus test results for 292 chemicals: from hazard identification to risk assessment application. [PDF]

Arch Toxicol, 2022
Kuo B, Beal MA, Wills JW, White PA, Marchetti F, Nong A, Barton-Maclaren TS, Houck K, Yauk CL.   +8 more
europepmc   +1 more source

The VHL tumor suppressor at the crossroad of protein folding, aggregation, and cancer

Molecular Oncology, EarlyView.
Mutations, environmental stress, and chaperone dysfunction can destabilize pVHL, promoting its conversion from the native folded state into amyloid‐like assemblies. This transition may contribute to protein storage, cell dormancy, survival, and drug resistance.
Lara Abad, Silvio Carlo Ermanno Tosatto, Emanuela Leonardi   +2 more
wiley   +1 more source

Hazard identification and characterization of leachable chemicals from plastic products - a new PARC project. [PDF]

Front Toxicol
Dirven H, Bogusz A, Bouwmeester H, Busch M, Duflos G, Eriksen GS, Fardilha M, Flores-Gomez D, Franko N, Gaté L, Guichard Y, Silva MJ, Kamstra JH, Kasiotis KM, Kim S, Kim YJ, Kim Y, van der Koogh E, Loureiro S, Louro H, Machera K, Pieters RHH, Spyropoulou A, Tzanetou EN, Malheiro C, Ravnjak T, Repetto G, Rivière G, Ryu CS, Papadopoulou EA, Aliferis KA, Solhaug A, Dolenc MS, Štampar M, Tavares AM, Tollefsen KE, Ventura C, Walkowiak R, Zobl W, Žegura B, Snapkow I, Herzke D.   +41 more
europepmc   +1 more source

New Approach Methods for Hazard Identification: A Case Study with Azole Fungicides Affecting Molecular Targets Associated with the Adverse Outcome Pathway for Cholestasis. [PDF]

Cells, 2022
Knebel C, Süssmuth RD, Hammer HS, Braeuning A, Marx-Stoelting P.   +4 more
europepmc   +1 more source

Extracellular vesicle lipidomics liquid biopsy reveals systemic and tumor microenvironment metabolic reprogramming in ovarian cancer

Molecular Oncology, EarlyView.
Extracellular vesicle (EV) lipidomic profiling of plasma and ascites from patients with high‐grade serous ovarian cancer and of ovarian cancer cell lines reveals enrichment of triglycerides (TGs), diacylglycerols (DGs), phosphatidylcholine (PCs), sphingomyelins (SMs), reflecting tumor metabolic reprogramming.
Shikha Rani, Dominic Guanzon, Andrew Lai, Katherin Scholz‐Romero, Sarah Reed, Edita Ritmejeryte, Rohan Lourie, Naven Chetty, Kaltin Ferguson, Carlos Salomon   +9 more
wiley   +1 more source

Perspective on applicability of data-driven machine learning computational new approach methodologies for hazard identification in chemicals risk assessment. [PDF]

J Cheminform
Piir G, Sild S, Tcheremenskaia O, Di Consiglio E, Henriksson J, Gajewicz-Skretna A, Mombelli E, Roncaglioni A, Maran U.   +8 more
europepmc   +1 more source

Promoting the Quarry Workers' Hazard Identification Through Formal and Informal Safety Training. [PDF]

Saf Health Work, 2021
Bae H, Simmons DR, Polmear M.
europepmc   +1 more source

Predictive and prognostic biomarkers of Bacillus Calmette‐Guérin therapy failure in bladder cancer patients: A systematic review

Molecular Oncology, EarlyView.
High‐risk bladder cancer is typically treated with Bacillus Calmette‐Guérin (BCG), but 30–40% of patients relapse. No FDA‐ or CE‐approved biomarkers currently predict or prognosticate BCG failure. We systematically reviewed the literature and identified 72 eligible studies, revealing several promising biomarkers associated with BCG treatment response ...
Rui Ribeiro‐Pereira, Ana Teixeira‐Marques, Rui Freitas, João A Carvalho, Sara Monteiro‐Reis, Giorgio I. Russo, Rui Henrique, Carmen Jerónimo   +7 more
wiley   +1 more source